Infigratinib

Drug Profile

Infigratinib

Alternative Names: BGJ-398; NVP-BGJ398

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Novartis; Novartis Oncology
  • Class Aniline compounds; Antineoplastics; Methylurea compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Cholangiocarcinoma; Glioblastoma; Haematological malignancies; Malignant melanoma; Solid tumours

Most Recent Events

  • 10 Nov 2016 Novartis terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Spain, Germany, Canada, Australia, USA due to scientific and business considerations (PO) (NCT01820364)
  • 01 Aug 2016 Novartis completes a phase Ib trial for Solid tumours (combination therapy, late-stage disease) in USA, Australia Belgium, Canada, France, Germany, Italy, South Korea, the Netherlands, Singapore, Spain, Switzerland (NCT01928459; EudraCT2013-001018-14)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top